Figure 2.

Effect of PARP inhibition on E₂-stimulated expression of PDZK1 and cyclin D1. a MCF-7 cells were transduced with a viral vector encoding control shRNA or a shRNA targeting human PDZK1. Cells were then treated with E₂ for 48 h after which cell viability was assessed. ^¶Difference from untreated controls; ^§difference from E₂-treated cells; p < 0.05. b Cells were treated with E₂ for 48 h after which protein extracts were prepared and subjected to immunoblot analysis with antibodies to PDZK1, cyclin D1, PARP-1, or GAPDH. c Cells were treated with E₂ for 48 h in the absence or presence of increasing concentrations of TIQ-A. Protein extracts were prepared and subjected to immunoblot analysis with antibodies to PDZK1, cyclin D1, or GAPDH. d MCF-7 cells were transduced with a viral vector encoding control shRNA or a shRNA targeting human PARP-1. Cells were then treated with E₂ for 48 h after which protein extracts were prepared and subjected to immunoblot analysis with antibodies to PDZK1, cyclin D1, PARP-1, or GAPDH.